Development of Novel Nanobiosensor for Direct Measurement of the Oral Anticoagulant Agent: Dabigatran Etexilate
نویسندگان
چکیده
منابع مشابه
Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabi...
متن کاملdabigatran etexilate - a novel oral anticoagulant for bleeding complications
thromboembolic disease is a common cause of morbidity and mortality. thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. dabi...
متن کاملAdherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
The recent development of new oral anticoagulants, of which dabigatran etexilate is currently at the most advanced stage of development, is the greatest advance in the provision of convenient anticoagulation therapy for many years. A new oral anticoagulation treatment, dabigatran etexilate, is already on the market in Europe. The main interest probably will be to improve the prescription and th...
متن کاملDabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU and several other countries for the prevention of venous thromboembolism after elective hip and knee replacement, and is in advanced clinical development for other thromboembolic disorders. Dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for r...
متن کاملDRUG EVALUATION Dabigatran etexilate: an oral direct thrombin inhibitor
10.2217/14750708.5.5.685 © 2 Dabigatran etexilate is a direct thrombin inhibitor that offers potential advantages over existing anticoagulants for the prevention and treatment of venous and arterial thrombosis. It is administered orally, has a rapid onset of action, a predictable anticoagulant effect and does not require laboratory monitoring. Trial results indicate that dabigatran etexilate ha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2018
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2018-99-110689